Diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells from patients with previous drug-induced blistering disease: A pilot study

被引:7
作者
Lan, Cheng-Che E.
Wu, Ching-Shuang
Tsai, Pei-Chien
Chen, Gwo-Shing
机构
[1] Kaohsiung Med Univ Hosp, Dept Dermatol, Kaohsiung 100, Taiwan
[2] Kaohsiung Med Univ, Dept Publ Hlth, Kaohsiung, Taiwan
[3] Kaohsiung Med Univ, Coll Hlth Sci, Fac Biomed Lab Sci, Kaohsiung, Taiwan
[4] Kaohsiung Med Univ, Coll Med, Dept Dermatol, Kaohsiung, Taiwan
关键词
Stevens-Johnson syndrome; toxic epidermal nercolysis; peripheral blood mononuclear cell; soluble Fas ligand;
D O I
10.2340/00015555-0074
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Toxic epidermal necrolysis and Stevens-Johnson syndrome are severe blistering diseases generally considered to be hypersensitivity reaction to drugs. The aim of this study is to explore the diagnostic role of soluble Fas ligand secretion by peripheral blood mononuclear cells (PBMCs) in patients with previous drug-induced blistering diseases with or without stimulation with the offending drug. The results revealed that PBMCs from the patient group showed significant soluble Fas ligand secretion after stimulation with 100 mu g/ml culprit drug (p<0.05). No significant change was seen in the control groups (p>0.05). Taken as a group, PBMCs from the patient group secreted more soluble Fas ligand than the normal control group regardless of drug stimulation. These results indicate that individuals whose PBMCs are high secretors of soluble Fas ligand are prone to severe toxic epidermal necrolysis/Stevens-Johnson syndrome. The possibility of using soluble Fas ligand secretion as a tool for retrospective determination of culprit drugs in patients with previous drug-induced blistering disease awaits further investigation.
引用
收藏
页码:215 / 218
页数:4
相关论文
共 17 条
  • [1] Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand
    Abe, R
    Shimizu, T
    Shibaki, A
    Nakamura, H
    Watanabe, H
    Shimizu, H
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2003, 162 (05) : 1515 - 1520
  • [2] Toxic epidermal necrolysis
    Becker, DS
    [J]. LANCET, 1998, 351 (9113) : 1417 - 1420
  • [3] A marker for Stevens-Johnson syndrome
    Chung, WH
    Hung, SI
    Hong, HS
    Hsih, MS
    Yang, LC
    Ho, HC
    Wu, JY
    Chen, YT
    [J]. NATURE, 2004, 428 (6982) : 486 - 486
  • [4] HERTL M, 1995, J INVEST DERMATOL, V105, P95
  • [5] Diagnosis of drug hypersensitivity: lymphocyte transformation test and cytokines
    Merk, HF
    [J]. TOXICOLOGY, 2005, 209 (02) : 217 - 220
  • [6] Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases
    Nozawa, K
    Kayagaki, N
    Tokano, Y
    Yagita, H
    Okumura, K
    Hasimoto, H
    [J]. ARTHRITIS AND RHEUMATISM, 1997, 40 (06): : 1126 - 1129
  • [7] The lymphocyte transformation test for the diagnosis of drug allergy: Sensitivity and specificity
    Nyfeler, B
    Pichler, WJ
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 1997, 27 (02) : 175 - 181
  • [8] Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome:: A Retrospective, Multicenter Study
    Prins, C
    Vittorio, C
    Padilla, RS
    Hunziker, T
    Itin, P
    Förster, J
    Bröcker, EB
    Saurat, JH
    French, LE
    [J]. DERMATOLOGY, 2003, 207 (01) : 96 - 99
  • [9] Diagnostic evaluation of delayed hypersensitivity to systemically administered drugs
    Romano, A
    Torres, MJ
    Quaratino, D
    Di Fonso, M
    Perrone, MR
    Viola, M
    Venuti, A
    Blanca, M
    [J]. ALLERGY, 1999, 54 : 23 - 27
  • [10] Elevated soluble Fas production in SLE correlates with HLA status not with disease activity
    Rose, LM
    Latchman, DS
    Isenberg, DA
    [J]. LUPUS, 1997, 6 (09) : 717 - 722